Forecast

There is no analyst data available for this company.

News Go to news feed

Biolargo reports 66% revenue decline to $1.1 million in the quarter

Biolargo released results for the quarter ended March 31, 2026, recording a 66.06% decline in revenue compared with the same period last year. Revenue fell from $3.3 million to $1.1 million. » More on finanzen.net
BioLargo reports mixed Q4 2025 results: revenue decline, doubled services business

BioLargo reported total revenue of $7.8 million for 2025 and a net loss of $15.2 million. The services business doubled to $2.0 million, cash stood at $3.9 million, and the termination of the Pooph license led to significant revenue losses. The stock fell 5.32% pre-market and was trading near its 52-week low; management plans to focus on commercialization in Clyra Medical and AEC Water Treatment in 2026. EPS estimates for 2026 are -$0.01. » More on de.investing.com
BioLargo reports Q3 revenue halved and burdensome loan loss from legal dispute

BioLargo recorded a roughly 50% year-on-year revenue decline in the third quarter of 2025 and missed earnings expectations. A loan loss of $3.85 million from the legal dispute with Poof weighed on results; EPS remained negative and revenue was below forecasts. The stock fell 7.87% to $0.1699 and is trading near its 52-week low. The company holds $4.5 million in cash and continues to focus on PFAS remediation, sodium-based battery technology and the rollout of Clyra‑Medical to drive growth. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2024, BIOLARGO INC. has already paid €3.69 in dividends. The last payout was in March 2024.

Financials

In the last quarter, BIOLARGO INC. had revenue of €1.09M and net profit of -€2.42M

(EUR)	Jun 2026	YoY
Revenue	1.09M	53.59%
Gross profit	591.44K	50.94%
Net profit	-2.42M	139.73%
EBITDA	-3.17M	116.93%

Fundamentals

Metric	Value
Market capitalization	€27.7M
Number of shares	320.88M
52-week high/low	€0.20 - €0.069
Dividends	No
Beta	-0.12
P/E ratio	-2.21
PEG ratio	0.02
P/B ratio	-17.33
P/S ratio	7.86

Company profile

BioLargo, Inc. erfindet, entwickelt und vermarktet verschiedene Plattformtechnologien. Die Technologien des Unternehmens lösen schwierige Umweltprobleme wie die Verunreinigung durch Per- und Polyfluoralkylsubstanzen, fortschrittliche Wasser- und Abwasseraufbereitung, industrielle Geruchs- und VOC-Kontrolle, Luftqualitätskontrolle und Infektionskontrolle. Das Unternehmen verfügt über verschiedene erteilte Patente, hat eine Reihe von Produkten in der Pipeline und bietet einen umfassenden Service im Bereich Umwelttechnik. Zu den Produkten des Unternehmens gehören das Advanced Oxidation System, ein Wasseraufbereitungsgerät, das eine Reihe von oxidativen und energetischen Jod- und anderen Molekülarten erzeugt; der Aqueous Electrostatic Concentrator, ein Wasseraufbereitungssystem, das Per- und Polyfluoralkyl-Substanzen aus dem Wasser entfernt; CupriDyne Clean-Industrieprodukte, die schwierige Gerüche und flüchtige organische Verbindungen in verschiedenen industriellen Umgebungen reduzieren und beseitigen; und fortschrittliche Wundpflegeprodukte. BioLargo, Inc. wurde 1991 gegründet und hat seinen Sitz in Westminster, Kalifornien.

Name	BIOLARGO INC.
CEO	Dennis Calvert
Headquarters	Westminster, ca USA
Website	biolargo.com
Sector	Industrials
Industry	Building Products
IPO	03/22/2007
Employees	45